Nutropin Convenience In Depot Form Balances Lower Efficacy, FDA Finds
This article was originally published in Pharmaceutical Approvals Monthly
The dosing convenience of Genentech’s Nutropin Depot, administered once or twice a month, is likely to "compensate for the somewhat lesser efficacy" it has compared to growth hormone (GH) products that are administered daily, FDA’s Solomon Sobel, MD, director of the Metabolic and Endocrine Drug Products Division, said in review documents.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class